---
schema_version: "secwatch.filing_event.v1"
accession: "0001867096-24-000124"
form_type: "8-K"
ticker: "XERS"
cik: "0001867096"
company_name: "Xeris Biopharma Holdings, Inc."
filed_at: "2024-07-08T23:59:59+00:00"
generated_at: "2026-05-31T23:08:38.279194+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Xeris CEO Paul Edick steps down; John Shannon named CEO; Q2 revenue >$47M (+23% YoY)

## Summary
- CEO Paul R. Edick transitions to Senior Advisor effective Aug 1, 2024; John Shannon (President & COO) appointed new CEO and Board member.
- Marla S. Persky appointed Chairperson of the Board effective Aug 1, 2024.
- Preliminary Q2 2024 total revenue exceeds $47.0M, representing >23% growth over prior year.
- Year-end 2024 cash guidance reaffirmed at $55M to $75M.

## SEC filing metadata
- accession: 0001867096-24-000124
- form_type: 8-K
- ticker: XERS
- cik: 0001867096
- company_name: Xeris Biopharma Holdings, Inc.
- filed_at: 2024-07-08T23:59:59+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1867096/000186709624000124/0001867096-24-000124-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1867096/000186709624000124/xers-20240707.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001867096-24-000124
- JSON: https://secwatch.observer/filing/0001867096-24-000124.json
- Plain text: https://secwatch.observer/filing/0001867096-24-000124.txt

## Key facts
- Executive change
  Paul R. Edick resigned as Chairman of the Board at Xeris Biopharma Holdings, Inc..
  - Action: resigned
  - Role: Chairman of the Board
  source text: On July 8, 2024, the Company announced that, effective August 1, 2024 (the “Transition Date”), Paul R. Edick will transition from his role as Chief Executive Officer and Chairman of the Board of Directors of the Company (the “Board”) and will become a Senior Advisor to the Company.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1867096/000186709624000124/0001867096-24-000124-index.htm
- Executive change
  John Shannon was appointed as Class III Director at Xeris Biopharma Holdings, Inc..
  - Action: appointed
  - Role: Class III Director
  source text: The Board also approved the appointment of Mr. Shannon as a Class III director, effective as of the Transition Date.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1867096/000186709624000124/0001867096-24-000124-index.htm
- Executive change
  Paul R. Edick resigned as Chief Executive Officer at Xeris Biopharma Holdings, Inc..
  - Action: resigned
  - Role: Chief Executive Officer
  source text: On July 8, 2024, the Company announced that, effective August 1, 2024 (the “Transition Date”), Paul R. Edick will transition from his role as Chief Executive Officer and Chairman of the Board of Directors of the Company (the “Board”) and will become a Senior Advisor to the Company.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1867096/000186709624000124/0001867096-24-000124-index.htm
- Executive change
  Marla S. Persky was appointed as Chairperson of the Board at Xeris Biopharma Holdings, Inc..
  - Action: appointed
  - Role: Chairperson of the Board
  source text: Marla S. Persky, currently a Class III director of the Company, has been appointed by the Board to serve as the Chairperson of the Board, effective as of the Transition Date.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1867096/000186709624000124/0001867096-24-000124-index.htm
- Executive change
  John Shannon was appointed as Chief Executive Officer at Xeris Biopharma Holdings, Inc..
  - Action: appointed
  - Role: Chief Executive Officer
  source text: John Shannon, currently the Company’s President and Chief Operating Officer, has been appointed by the Board to serve as the Company’s Chief Executive Officer, effective as of the Transition Date.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1867096/000186709624000124/0001867096-24-000124-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.